Pfizer: Stagnation Is An Investment Opportunity

Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Despite recent stagnation, Pfizer has consistently maintained its dividend payout and remains undervalued. The company has a number of exciting drugs ramping up sales to cover the loss of exclusivity risks, and revenue has grown YoY.